Immutep (NASDAQ:IMMP) Stock Crosses Below 50 Day Moving Average – Time to Sell?

Immutep Limited (NASDAQ:IMMP)’s share price passed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $1.92 and traded as low as $1.88. Immutep shares last traded at $1.88, with a volume of 56,504 shares traded.

Immutep Trading Down 1.1 %

The stock has a 50-day moving average of $1.92 and a 200-day moving average of $2.03. The company has a debt-to-equity ratio of 0.01, a current ratio of 18.25 and a quick ratio of 18.25.

Institutional Trading of Immutep

Institutional investors and hedge funds have recently modified their holdings of the business. Fortitude Advisory Group L.L.C. bought a new position in shares of Immutep in the fourth quarter worth approximately $28,000. OLD Mission Capital LLC purchased a new position in Immutep in the 4th quarter worth approximately $36,000. Two Sigma Securities LLC bought a new position in shares of Immutep in the 4th quarter worth $74,000. ABC Arbitrage SA purchased a new stake in shares of Immutep during the 4th quarter valued at $152,000. Finally, XY Capital Ltd lifted its holdings in shares of Immutep by 52.0% during the 4th quarter. XY Capital Ltd now owns 164,655 shares of the biotechnology company’s stock worth $357,000 after acquiring an additional 56,306 shares during the last quarter. Hedge funds and other institutional investors own 2.32% of the company’s stock.

Immutep Company Profile

Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system.